ArticleCancer research2010
Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin.
Article in Cancer research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 1 synthesis or guideline pooled it, 175 citations in OpenAlex.
- Association between BRCA1 P871L polymorphism and cancer risk: evidence from a meta-analysis.Oncotarget · 2017Pooled it
- Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Trial
- Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2015Trial
- Targeted Therapies for Each Subtype of Breast Cancer.MedComm · 2026Review
- Combinative Treatment of the PARP Inhibitor Olaparib and Antimetastasis Ruthenium(II)-Arene Compound RAPTA-T for Triple-NegativeInternational journal of molecular sciences · 2025Article
- PJ34 prevents cisplatin-induced hair cell loss via inhibition of PARP-1-AIF parthanatos.Biomolecules & biomedicine · 2025Article
- Theranostics for Triple-Negative Breast Cancer.Diagnostics (Basel, Switzerland) · 2023Review
- Prediction of small molecule drug-miRNA associations based on GNNs and CNNs.Frontiers in genetics · 2023Article
- Article
- Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers.Breast cancer research : BCR · 2022Article
- Current landscape of personalized clinical treatments for triple-negative breast cancer.Frontiers in pharmacology · 2022Review
- Review
- The p53 family member p73 in the regulation of cell stress response.Biology direct · 2021Review
- Differential whole-genome doubling and homologous recombination deficiencies across breast cancer subtypes from the Taiwanese population.Communications biology · 2021Article
- Article
- Poly (ADP-Ribose) Polymerase Inhibitor, ABT888, Improved Cisplatin Effect in Human Oral Cell Carcinoma.Biomedicines · 2021Article
- p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors.JCI insight · 2021Article
- The cancer-testis gene,Cancer biology & medicine · 2021Article
- Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy.ChemMedChem · 2020Review
- Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The basal-like subtype of breast cancer is characterized by a triple-negative (TN) phenotype (estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2/neu negative). TN breast cancers share similar gene expression profiles and DNA repair deficiencies with BRCA1-associated breast cancers. BRCA1-mutant cells exhibit sensitivity to gemcitabine, cisplatin, and poly(ADP-ribose) polymerase (PARP) inhibition; therefore, we hypothesized that TN cancer cells may also exhibit sensitivity to these drugs. In this study, we report that TN breast cancer cells are more sensitive to these drugs compared with non-TN breast cancer cells. Moreover, combination treatments indicated that PARP inhibition by the small-molecule inhibitor PJ34 or siRNA knockdown synergized with gemcitabine and cisplatin in TN cells but not in luminal cancer cells. TN cells exhibited reduced repair of UV-induced cyclobutane pyrimidine dimers after PARP inhibition, suggesting that the synergistic effect of PJ34 and gemcitabine or cisplatin reflected inefficient nucleotide excision repair. Mechanistic investigations revealed that in TN cells, PJ34 reduced the levels of ΔNp63α with a concurrent increase in p73 and its downstream target p21. Thus, the sensitivity to combination treatment seemed to be mediated by sustained DNA damage and inefficient DNA repair triggering p63/p73-mediated apoptosis. Our results suggest a novel therapeutic strategy to treat women with TN breast cancer, an aggressive disease that presently lacks effective treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.